✥ Served in part-time or interim operational roles in early stage companies to lead scientific teams, create product strategy and establish internal processes to support company growth✥ Conducted product market assessments (feasibility, market size, competition, target product profile, intended use).✥ Supported development of value proposition, product feasibility, and competitive analysis.✥ Developed strategy, recruited staff, and led the implementation of Quality Management System (GMP).✥ Evaluated IT and informatics infrastructure for research and regulated laboratories (GXP, CLIA, HIPAA).✥ Performed due diligence for venture investors.

Providing biotechnology, pharmaceutical related business, scientific and strategic development advice, consultation and services. This includes identification and assessment of opportunities for early-stage equity investments, in-kind services and/or new venture incubator resources.✥ Provided scientific guidance to portfolio companies.✥ Supported academic partnerships.✥ Participated in due diligence for potential investments.

Interim Chief Scientific Officer October 2017 - July 2020Advisor for Informatics and Modeling, July 2020 - PresentDeveloping intrinsically membrane permeable macrocycle therapeutics targeting important intracellular protein-protein interactions.

✥ CHEM 241(Molecular Thermodynamics) - Lecturer✥ Entrepreneurship Center Mentor (Idea to IPO class, Lean LaunchPad for Life Sciences, Startup 101)✥ Graduate Student Internships for Career Exploration Program (GSICE)✥ MIND: Motivating INformed Decisions Program

Executive-level manager responsible for overall design, implementation, support and validation of informatics, biostatistics, and information technology systems.✥ Led team to establish the reproducibility of proprietary flow-cytometry based proteomics technology. ✥ Served as key member of the cross-functional team that conducted clinical trials to establish and validate clinical performance for predictive tests in AML. Final assays showed longitudinal reproducibility >95%. ✥ Participated in venture capital fund raising, corporate partnering, served on Joint Steering Committees.✥ Led team to validate software for GXP, CLIA, and 21 CFR Part 11 to meet FDA compliance regulations. ✥Led multiple internal Quality System audits and successfully completed multiple external audits.

Joined Almaden Services Research group to explore business and information services in Healthcare and Life Sciences.✥ Co-organized an international conference on needs and emerging markets in biomedical and health informatics.✥ Participated in Global Technology Outlook, IBM Research's vision of the future for IT.✥ Led technology assessment briefings for the US Army Logistics Transformation Agency on biotech, nanotech, technology tracking, business process transformation.

✥ Led all aspects of the preclinical drug discovery operations. ✥ Helped secure a vital corporate partnership and performed feasibility studies with large pharmaceutical partner.✥ Worked closely with engineering teams to prototype and establish proof-of-concept for two label-free assay platforms.✥ Participated in $43 million Series D financing, completed 3 acquisitions and due diligence on potential acquisitions.

✥ Led team responsible for technology transfer to DuPont Pharmaceuticals of CombiChem's computational drug discovery tools.

✥ Led CombiChem's computational chemistry team, including software development, data analysis, chemical informatics and IT. ✥ Participated in scientific, managerial, and business development aspects of corporate partnering.

✥ Served as project lead for several partnered and internal therapeutic discovery projects.✥ Developed software to support combinatorial chemistry - molecular diversity, combinatorial library design, and web-based structure-based drug discovery.✥ Participated in securing several corporate partnerships for combinatorial chemistry platform.